Momat - instructions for use, analogs, reviews and release forms (cream 0.1%, ointment C, nasal spray or nasal drops Reno Advance) hormonal drug for the treatment of psoriasis, allergic rhinitis in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Momat. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Momata in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of the Momata in the presence of existing structural analogues.Use for the treatment of psoriasis, dermatitis and allergic rhinitis in adults, children, as well as during pregnancy and lactation. Composition of the hormonal drug.

Momat - a preparation with antiallergic and anti-inflammatory action for topical application and in ENT practice.

Mometasone (the active substance of the drug Momat) is a synthetic glucocorticosteroid (GCS) for topical application. Has anti-inflammatory and antiallergic effect when used in doses, in which no systemic effects occur. It inhibits the release of inflammatory mediators. Increases the production of lipomodulin, which is an inhibitor of phospholipase A, which causes a decrease in the release of arachidonic acid and, accordingly, inhibition of the synthesis of metabolic products of arachidonic acid-cyclic endoperoxides, prostaglandins. It prevents the accumulation of neutrophils, which reduces inflammatory exudate and production of lymphokines, inhibits the migration of macrophages, leads to a decrease in the processes of infiltration and granulation. Reduces inflammation due to decreased formation of chemotaxis substance (influence on "late" allergy reactions),inhibits the development of an allergic reaction of an immediate type (due to inhibition of the production of arachidonic acid metabolites and a decrease in the release of inflammatory mediators from mast cells).

Azelastine, a derivative of phthalazinone, is an antiallergic, long-acting agent. Azelastine is a selective blocker of histamine H1 receptors, has antihistamine, anti-allergic and membrane-stabilizing action, reduces capillary permeability and exudation, stabilizes mast cell membranes and prevents the release of biologically active substances (histamine, serotonin, leukotrienes, platelet activating factor, etc.) causing bronchospasm and contributing to the development of early and late stage of allergic reactions and inflammation.

Composition

Mometasone furoate + excipients.

Azelastine hydrochloride + mometasone furoate + auxiliary substances (Momo Reno Advance).

Mometasone furoate + Salicylic acid + excipients (Moment C).

Pharmacokinetics

Mometasone furoate

In case of intranasal application, the system bioavailability of mometasone furoate is less than 1% (with the sensitivity of the 0.25 pg / ml detection method).The suspension of mometasone is very poorly absorbed from the gastrointestinal tract, and then a small amount of mometasone suspension that can enter the digestive tract after nasal inhalation is subjected to active primary metabolism before excretion with urine or bile.

Azelastine hydrochloride

Bioavailability after intranasal application is about 40%. Intranasal use in patients with allergic rhinitis causes an increase in the level of azelastine in blood plasma compared to healthy volunteers. Metabolised in the liver by oxidation with the participation of the cytochrome P450 system with the formation of the active metabolite desmethylazelastine. It is excreted mainly by the kidneys in the form of inactive metabolites.

Indications

For cream:

• inflammatory phenomena and itching with dermatoses that are amenable to glucocorticosteroid therapy.

For ointments:

• inflammatory phenomena and itching in dermatoses (psoriasis, atopic dermatitis, seborrheic dermatitis), amenable to glucocorticosteroid therapy, in adults and children over 2 years of age.

For the spray:

• seasonal allergic rhinitis in adults from 18 years of age.

Forms of release

Spray nasal dosed (Momo Reno Advance) (sometimes mistakenly called drops in the nose).

Cream for external use 0.1%.

Ointment for external use 0.1%.

Ointment for external use (Momat C).

Instructions for use and how to use them

Ointment or cream

Outwardly. A thin layer of ointment or cream Momat is applied to the affected areas of the skin 1 time per day. The duration of the course of treatment is determined by its effectiveness, tolerability of the drug, as well as the presence and severity of side effects.

Spray nasal

The drug is used intranasally (in the nose). Inhalation of the suspension contained in the vial is carried out by means of a special dispensing nozzle on the vial.

Assign a 1 dose of spray (azelastine hydrochloride 140 μg / mometasone furoate 50 μg) in each nostril 2 times a day in the morning and evening. The duration of the course of treatment is 2 weeks.

Guide for using a vial with a dosing device

1. Remove the protective cap.

2. Before the first application of the nasal spray, it is necessary to "calibrate" it by pressing the dosing device about 10 times. If the nasal spray has not been used for 7 days or longer, you need to re-calibrate by pressing the dosing device about 2 times, or by pressing the cover until spray splashes appear.It is necessary to place the index and middle fingers on the sides of the nasal adapter, and the thumb on the bottom of the bottle and, making a breath through the nose, press. Do not pierce the nasal adapter. Do not spray into eyes when spraying.

3. Clean the nostrils before use. Clamp one nostril, and insert the end portion of the nasal adapter into another nostril, while holding the vial vertically. Quickly and abruptly push the adapter. Do not spray on the nasal septum.

4. Exhale through the mouth.

5. Repeat the steps described in step 3 for the other nostril.

6. Wipe the nasal adapter with a clean cloth and put on the protective cap.

Instructions for cleaning the nasal adapter

1. Remove the protective cap.

2. Carefully remove the nasal adapter by pulling it upwards.

3. Rinse the nasal adapter with cold running water from both sides and dry. Do not use any auxiliary items (such as needles or sharp objects) to clean the adapter to avoid damaging it.

4. Rinse the protective cap with cold running water and dry.

5. Install the nasal adapter to its original position.Make sure that the stem of the vial is placed in the center of the nasal adapter.

6. Calibrate by pressing the metering device 2 times, or by pressing the cover until a fine dispersion starts to stick out firmly when pressed. Do not spray into the eyes.

7. Put the protective cap on.

Ointment Momat C

Outwardly. A thin layer of ointment should be applied to the affected areas of the skin 2 times a day, in the morning and in the evening. The maximum daily dose is 15 g.

Side effect

Cream and ointment

• mild or moderate burning at the site of ointment application;
• itching;
• peeling;
• irritation, maceration of the skin;
• dry skin;
• folliculitis;
• acne (pink acne);
• hypopigmentation;
• perioral dermatitis;
• allergic contact dermatitis;
• appearance of atrophic skin bands;
• prickly heat;
• secondary infections;
• hypertrichosis;
• children may suppress the function of the hypothalamic-pituitary-adrenal system with the development of Cushing's syndrome.

Spray in the nose

• headache;
• dysgeusia (unpleasant taste) as a result of improper application, namely, with excessive head deflection back during insertion;
• dizziness (can be caused by the disease itself);
• sensation of irritation of the mucous membrane of the pharynx;
• nausea;
• nasal bleeding;
• discomfort in the nasal cavity (burning sensation, itching);
• ulceration of the nasal mucosa;
• sneezing;
• pharyngitis;
• sinusitis;
• upper respiratory tract infection;
• hypersensitivity;
• anaphylactoid reactions;
• hives;
• rash;
• itching;
• fatigue;
• drowsiness;
• weakness (can be caused by the disease itself);
• glaucoma;
• cataract.

Contraindications

Cream and ointment

• rosacea;
• perioral dermatitis;
• bacterial, viral (Herpes simplex (herpes simplex), chicken pox, Herpes zoster) or fungal skin infections;
• tuberculosis, syphilis;
• postvaccinal reactions;
• children under 2 years (for ointment);
• pregnancy (use on large areas of the skin, long-term treatment);
• lactation period (use in high doses and / or for a long time);
• increased sensitivity to GCS or to the components of the drug.

Spray nasal

• recent surgery or injury to the nose with damage to the mucous membrane of the nasal cavity - until the wound is healed (due to the inhibitory effect of GCS on the healing process);
• children and adolescents under 18 years of age (due to the lack of relevant data);
• hypersensitivity to any of the components of the drug.

Application in pregnancy and lactation

Appropriately planned and well-controlled studies of the drug in pregnant women were not conducted.

Azelastine hydrochloride is able to cause toxicity during fetal development in mice, rats and rabbits.

Use of the drug Momat during pregnancy and during breastfeeding is contraindicated.

Use in children

Contraindicated use of the drug Momat Rino Advance in children and adolescents under the age of 18 (due to the lack of relevant data).

Ointment is contraindicated in children under 2 years of age.

special instructions

As with any long-term treatment, patients who use the Momat Rino Advance nasal spray for several months and longer should periodically check with the doctor for possible changes in the nasal mucosa, perforation of the nasal septum (very rarely), and the possible development of systemic side effects.In case of development of a local fungal infection of the nose or throat, it may be necessary to stop the therapy with the Momat Rino Advance nasal spray and carry out special treatment. In the case of the development of persistent irritation of the nasopharynx, it is necessary to solve the problem of discontinuing therapy.

Patients who switch to nasal spray therapy Momat Rino Advance after long-term therapy with glucocorticosteroids (GCS) systemic action, require special attention. The abolition of SCS systemic action in such patients can lead to an insufficient adrenal function, the subsequent restoration of which can take up to several months. If signs of adrenal insufficiency appear, the systemic GCS should be resumed and other necessary measures taken.

During the transition from systemic SCS treatment to treatment with nasal spray Momat Rhino Advance, in some patients, initial symptoms of cancellation of systemic SCS (for example, joint and / or muscle pain, fatigue and depression) may occur, despite a decrease in the severity of symptoms associated with defeat of the nasal mucosa; such patients need to specifically convince in the advisability of continuing treatment with nasal spray Momat Rino Advance.Transition from systemic to local SCS can also reveal already existing, but masked by GCS therapy of systemic action, allergic diseases such as allergic conjunctivitis and eczema.

When intranasal steroids are used at doses that are higher than recommended, or at recommended doses in sensitive patients, systemic effects of GCS and suppression of adrenal function may develop. If such changes occur, the use of the Momat Rino Advance nasal spray should be gradually stopped, in accordance with the procedures adopted to stop oral glucocorticosteroids.

Patients undergoing SCS treatment have a potentially reduced immune reactivity and should be warned about the increased risk of infection in case of contact with patients with certain infectious diseases (for example, chicken pox, measles) and the need for medical advice if such contact occurs .

If signs of severe bacterial infection (eg fever, persistent and sharp pain on one side of the face or toothache, swelling in the orbital or periorbital area) appear, immediate medical attention is required.

GCS for nasal and inhalation use can cause the development of glaucoma and / or cataracts. Therefore, close monitoring of patients with vision changes, as well as for patients who have previously been noted increased intraocular pressure, glaucoma and / or cataracts.

Impact on the ability to drive vehicles and manage mechanisms

In rare cases fatigue, fatigue, dizziness and weakness, which can be a consequence of the disease itself, can develop with the application of nasal spray Momat Rino Advance. In such cases, you should avoid driving and working with complex machinery.

Drug Interactions

Azelastine

In the intranasal application of azelastine, there is no clinically relevant interaction with other drugs.

Mometasone furoate

Combination therapy with loratadine was well tolerated by patients. At the same time, there was no evidence of any drug effect on the concentration of loratadine or its main metabolite in blood plasma. In these studies, mometasone furoate in the blood plasma was not detected (with the sensitivity of the method of determining 50 pg / ml).

Analogues of the drug Momat

Structural analogs for the active substance:

• Avecourt;
• Asmaneks Twistheiler;
• Galazolin Allergo;
• Gistan H;
• Desrinitis;
• Momo Reno Advance;
• Moment C;
• Momederm;
• Mometasone;
• Mometasone furoate;
• Monovo;
• Nazonex;
• Nosephrine;
• Silkarene;
• Uniderm;
• Elokom;
• Elokom Lotion;
• Elokom S.

Similar medicines:

Other medicines: